Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30106% above fair value

$146.95−0.23 (-0.16%)

Close on Nov 12, 2026Market cap $362.55BP/E 151.5Yield 2.23%

Merck EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Merck's EV/EBITDA was 17.7× on Jan 29, 2021, against 15.1× a year earlier. Over the last 5 years it ranged from 12.5× to 20.6×, with a median of 16.7×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2021	Jan 29, 2021	17.7×	−1.0
2020	Dec 31, 2020	18.7×	+2.7
2019	Dec 31, 2019	16.0×	−0.4
2018	Dec 31, 2018	16.4×	−3.2
2017	Dec 29, 2017	19.6×	+6.4
2016	Dec 30, 2016	13.2×	+6.2
2015	Dec 31, 2015	7.1×	−6.7
2014	Dec 31, 2014	13.8×	+4.3
2013	Dec 31, 2013	9.5×	+1.8
2012	Dec 31, 2012	7.7×	–